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ORIGINAL ARTICLE
Introduction: Even for patients with clinical N0 non–small-cell 
lung cancer (NSCLC), several invasive tests are available to patho-
logically confirm the presumptive mediastinal stage by radiologic 
modalities. The aim of this study was to determine a high-risk 
population for mediastinal nodal metastasis in patients with clinical 
stage IA NSCLC, which would be suitable for mediastinal staging 
by invasive modalities, such as mediastinoscopy or endobronchial 
ultrasound-guided transbronchial needle aspiration.
Methods: We retrospectively reviewed peripheral clinical stage IA 
NSCLC patients who had undergone surgical resection with system-
atic mediastinal lymphadenectomy from 1998 to 2011. To identify 
predictors for mediastinal nodal metastasis, univariate and multivari-
ate logistic regression analyses were performed. For the significant 
factors, optimal cutoff points were determined with a receiver operat-
ing characteristic analysis.
Results: Among the 894 patients eligible for this study, the overall 
prevalence of mediastinal nodal metastasis was 7.5%. The following 
four predictors for mediastinal nodal metastasis were identified: age, 
preoperative serum carcinoembryonic antigen level, tumor size on 
preoperative radiologic findings, and consolidation/tumor ratio on 
high-resolution computed tomography. Of the patients with all four 
predictors identified by the multivariate analyses and receiver operat-
ing characteristic analyses (age ≤67 years, carcinoembryonic antigen 
≥ 3.5 ng/ml, tumor size ≥ 2.0 cm, and consolidation/tumor ratio ≥ 
89%), the prevalence of mediastinal nodal metastasis was 33.8%.
Conclusions: Among the clinical stage IA NSCLC patients in 
whom all four predictors were identified, one third of the patients 
showed mediastinal nodal metastasis, and thus, those patients should 
be a target for mediastinal node assessment by invasive modalities, 
such as mediastinoscopy or endobronchial ultrasound-guided trans-
bronchial needle aspiration.
Key Words: Non–small-cell lung cancer, Early-stage non–
small-cell lung cancer, Mediastinal lymph node metastasis, 
Mediastinoscopy, Endobronchial ultrasound-guided transbronchial 
needle aspiration.
(J Thorac Oncol. 2012;7: 1246–1251)
Because of the advent of refined chest high-resolution com-puted tomography (HRCT) and computed tomography (CT) 
screening programs, smaller lung cancers are being discovered.1 
Surgical pulmonary resection is the first treatment of choice for 
early-stage non–small-cell lung cancer (NSCLC) patients; how-
ever, even small NSCLCs show mediastinal node involvement. 
Among early NSCLC patients with a peripheral tumor 2 cm or 
less in diameter, the nodal metastatic rate has been reported to 
be 15% to 20%,2–5 and pathologically diagnosed node metastasis 
is one of the strongest independent predictors for poor survival 
in curatively resected clinical stage I NSCLC patients.6 If medi-
astinal node involvement is identified preoperatively, surgical 
treatment alone has low benefit,7 and neoadjuvant therapy before 
surgical resection could improve the survival of those patients.8,9 
Thus, accurate preoperative mediastinal staging is important to 
select the optimal treatment for NSCLC patients.
The CT size criteria for node metastasis has limita-
tions because of benign nodes enlargement and normal-sized 
metastatic nodes.10 Positron emission tomography combined 
with CT (PET-CT) is increasingly used for nodal staging in 
NSCLC patients; however, the efficacy of PET-CT assessment 
of the mediastinum is still controversial because of its high 
false-positive rate.11
Mediastinoscopy and endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) are safe tech-
niques for the pathological assessment of mediastinal lymph 
nodes.12,13 These modalities show a high diagnostic yield, and 
are indicative for patients with suspected mediastinal nodal 
metastasis on chest CT or PET-CT, and even for patients 
having clinical N0 disease, to identify occult nodal metasta-
sis. However, given the reported low prevalence of medias-
tinal nodal metastasis of approximately 7% in clinical stage 
I NSCLC patients,14 the selective use of mediastinoscopy or 
EBUS-TBNA in clinical stage I NSCLC patients with high-risk 
factors for mediastinal nodal metastasis has been suggested.
The aim of this study was to determine a high-risk 
population for mediastinal nodal metastasis exclusively in 
clinical stage IA NSCLC patients, which would be suitable 
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for mediastinal node assessment by invasive modalities, such 
as mediastinoscopy or EBUS-TBNA. We retrospectively 
reviewed peripheral clinical stage IA NSCLC patients who 
had undergone surgical pulmonary resection with systematic 
mediastinal lymphadenectomy at the Niigata Cancer Center 
Hospital (Niigata, Japan), and sought to investigate the inde-
pendent demographic and clinical predictors for pathologi-
cally diagnosed mediastinal nodal metastasis in those patients.
PATIENTS AND METHODS
Patients
The study retrospectively evaluated clinical stage IA 
NSCLC patients (cT1a or 1b N0 M0 staged according to the 
7th edition of the tumor, node, metastasis [TNM] classifica-
tion) who had undergone surgical pulmonary resection with 
systematic mediastinal lymphadenectomy at our institution. 
Patients who underwent wedge resection, who underwent sys-
tematic hilar lymphadenectomy or node sampling only, had 
a history of previous treatment, had nonperipherally located 
carcinoma that was visible on bronchoscopy, or had a positive 
node on CT or PET-CT were excluded from the study.
All patients underwent careful preoperative staging with 
CT scanning. Mediastinal lymph nodes were considered to be 
positive by CT-scan criteria when their short axis was 1 cm 
or more in size. Additional diagnostic testing (brain magnetic 
resonance imaging and bone scan) was performed at the dis-
cretion of the individual surgeon or physician, according to 
patient symptoms and clinical findings. PET-CT was intro-
duced to our institution in 2010, and has since been performed 
for preoperative staging when appropriate. In the patients in 
whom PET-CT was performed, our radiologists comprehen-
sively diagnosed a node positive when the described meta-
bolic activity in the mediastinum exceeded background levels 
accompanied by a node enlargement on CT or the clinical 
findings were consistent with suspected nodal metastasis. No 
invasive modalities for mediastinal staging, such as mediasti-
noscopy or EBUS-TBNA, were used preoperatively.
Between January 1998 and December 2011, a total of 
1567 patients with clinical stage IA NSCLC underwent pul-
monary resection at the Niigata Cancer Center Hospital. Of 
these, 894 patients met the inclusion criteria and were enrolled.
This study was approved by the institutional review 
board of the Niigata Cancer Center Hospital. Because this 
was a retrospective study, the need to obtain written informed 
consent from each patient was waived.
Demographic and clinical parameters: We reviewed the medi-
cal records of each patient for demographic and clinical data 
including age (≤66 years or >66 years), sex, smoking sta-
tus (Brinkman index15; 0, >0–1000, or ≥1000), preoperative 
serum carcinoembryonic antigen (CEA) level (<5 ng/ml or 
≥5 ng/ml), tumor location (right upper lobe, right middle lobe, 
right lower lobe, left upper lobe, or left lower lobe), tumor 
size on preoperative radiologic findings (≤2 cm or >2–3 cm), 
preoperative cancer diagnosis (no diagnosis, diagnosed by 
bronchoscopy, diagnosed by CT-guided transthoracic needle 
aspiration biopsy [CTNB]), tumor histology (adenocarci-
noma, squamous-cell carcinoma, or other cell types), PET-CT 
(performed or not performed), and consolidation/tumor size 
ratio16 (Cons/Tumor ratio; ≤75% or >75%) on high-resolution 
computed tomography (HRCT).
On a univariate analysis for age, the patients were divided 
into two groups according to the median age of 66 years. The 
Brinkman index was scored as the number of cigarettes smoked 
per day multiplied by the number of years since smoking 
started.15 The cutoff point of the Brinkman index on a univari-
ate analysis was set at 1000 as used in a previous report,17 and a 
Brinkman index 1000 or more indicates quite heavy smoking. 
The cutoff at the normal upper limit of CEA was set at 5 ng/ml. 
For preoperative pathologic diagnosis of lung carcinoma, every 
patient with a peripheral lung nodule routinely underwent bron-
choscopy, and transbronchial biopsy or the bronchial brushing 
for cytology was attempted. Percutaneous CTNB was indicated 
in lesions that were not visible on chest fluoroscopy or were 
too close to the visceral pleura to access by the bronchoscopic 
approach. No modalities for diagnosis of peripheral lung nod-
ule were performed when the tumor was too small or located in 
an area difficult to access by both the bronchoscopic approach 
and percutaneous CTNB. The Cons/Tumor ratio was defined as 
the maximum diameter of consolidation divided by the maxi-
mum tumor diameter on HRCT.16
Surgical resection: All of the surgical resections and medi-
astinal lymphadenectomies were conducted by thoracic sur-
geons at the Niigata Cancer Center Hospital. Pneumonectomy, 
bilobectomy, lobectomy, or segmentectomy was performed 
in the patients in the current study. Because anatomical seg-
mentectomy could procure an adequate number of N1 and 
N2 nodes for pathological examination compared with lobec-
tomy,18 the patients who underwent segmentectomy were 
included. The dissected lymph nodes were examined histo-
logically after hematoxylin and eosin staining.
Statistical analysis: A univariate analysis and multivariate 
logistic regression analysis were performed to identify predic-
tors for mediastinal nodal metastasis. Fisher’s exact test and 
the χ2 test were used for the univariate analyses. A stepwise 
selection method was used to build logistic regression mod-
els. In the multivariate analysis, categorical variables (sex, 
tumor location, preoperative cancer diagnosis, tumor histol-
ogy, and PET-CT) and continuous variables (age, Brinkman 
index, preoperative serum CEA level, tumor size on preop-
erative radiologic findings, and Cons/Tumor ratio on HRCT) 
were assessed to identify independent predictors. For factors 
significant in the multivariate analysis, a receiver operating 
characteristic (ROC) analysis was performed. The optimal 
cutoff points were evaluated by Youden’s index.
A p value less than 0.05 was considered statistically sig-
nificant. All analyses were performed using IBM SPSS 20.0 
(IBM Co., Chicago, IL).
RESULTS
Of the 894 patients eligible for this study, 456 were men 
and 438 were women, and the median age was 66 years (range, 
28–86 years). On pathologic diagnosis postresection, 67 
patients developed mediastinal nodal metastasis, and the prev-
alence of mediastinal nodal metastasis was 7.5% (Table 1). 
Of the 67 patients having metastatic mediastinal lymph nodes, 
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56 patients (83.6%) had cancer metastasis in superior medi-
astinal nodes and/or aortic nodes, 28 patients (41.8%) had 
metastasis in inferior mediastinal nodes, and 17 patients 
(25.4%) had metastasis in both of them. In addition, 41 of 
the 67 patients (61.2%) developed metastatic N1 nodes. Six 
hundred and sixty-six patients (74.5%) underwent lobectomy, 
219 (24.5%) underwent segmentectomy, eight (0.9%) under-
went bilobectomy, and one (0.1%) underwent pneumonec-
tomy. The median tumor size was 1.7 cm (range, 0.7–3.0 cm) 
on preoperative radiologic findings: 415 patients(46.4%) had 
clinical T1a disease and 479 (53.6%) had clinical T1b disease. 
Preoperatively, 536 patients (60.0%) had a tumor pathologi-
cally diagnosed as lung carcinoma (by bronchoscopy in 439 
patients and by CTNB in 97), and 358 patients (40.0%) had 
no cancer diagnosis. The most dominant histological subtype 
of the tumor was adenocarcinoma (n = 794, 88.8%), and 81 
(9.1%) patients had squamous-cell carcinoma. Tumor histol-
ogy other than adenocarcinoma or squamous-cell carcinoma 
(n = 19, 2.1%) was large-cell carcinoma (n = 7), adenosqua-
mous carcinoma (n = 6), sarcomatoid carcinoma (n = 3), and 
carcinoid tumor (n = 3).
The univariate analysis identified the following four 
variables as significant predictors for mediastinal nodal 
metastasis: preoperative serum CEA level of 5 ng/ml or more 
(p = 0.003), tumor size more than 2 cm on preoperative radio-
logic findings (p < 0.001), preoperative cancer diagnosis by 
bronchoscopy (p = 0.001), and Cons/Tumor ratio more than 
75% on HRCT (p < 0.001) (Table 1). Age, sex, smoking sta-
tus, tumor location, tumor histology, and whether PET-CT was 
performed were not identified as significant predictors.
A multivariate analysis revealed the following four sig-
nificant predictors for mediastinal nodal metastasis: age (odds 
ratio [OR]: 0.954, p = 0.001), preoperative serum CEA level 
(OR: 1.054, p = 0.017), tumor size on preoperative radiologic 
findings (OR: 1.084, p = 0.003), and Cons/Tumor ratio on 
HRCT (OR: 1.126, p < 0.001) (Table 2). Age of the patient 
was identified as a significant predictor even though it was not 
identified on the univariate analysis.
Figure 1 shows ROC curves generated based on the dis-
tributions of each significant variable according to mediastinal 
nodal metastasis. The area under the ROC curve (AUC) values 
for age, preoperative serum CEA level, tumor size on preoper-
ative radiologic findings, and the Cons/Tumor ratio on HRCT 
were 0.597 (95% confidence interval [CI] 0.526–0.667), 
TABLE 1. Demographic and Clinical Characteristics and 
Univariate Analysis of the Prevalence of Mediastinal Lymph 
Node Metastasis for the 894 Patients with Clinical Stage IA 
NSCLC
Variable
No. of 
Patients 
(%)
Mediastinal 
Lymph 
Node 
Metastasis 
(%) p
All patients 894 (100) 67 (7.5)
Agea
 ≤66 yrs 456 (51.8) 42 (9.2)
 >66 yrs 438 (49.2) 25 (5.7) 0.063
Sex
 Male 438 (49.0) 27 (6.2)
 Female 456 (51.0) 40 (8.8) 0.176
Smoking status (Brinkman indexb)
 0 432 (48.3) 26 (6.0)
 >0–1000 273 (30.5) 21 (7.7)
 ≥1000 189 (21.2) 20 (10.6) 0.137
CEAc
 <5 ng/ml 749 (83.8) 47 (6.3)
 ≥5 ng/ml 145 (16.2) 20 (13.8) 0.003d
Tumor location
 Right upper lobe 304 (34.0) 22 (7.2)
 Right middle 
lobe
78 (8.7) 8 (10.3)
 Right lower lobe 157 (17.6) 14 (8.9)
 Left upper lobe 223 (24.9) 14 (6.3)
 Left lower lobe 132 (14.8) 9 (6.8) 0.753
Tumor size (radiologic)
 ≤2 cm 415 (46.4) 16 (3.9)
 >2–3 cm 479 (53.6) 51 (10.6) <0.001d
Preoperative cancer diagnosis
 No diagnosis 358 (40.0) 16 (4.7)
 By bronchoscopy 439 (49.1) 48 (10.9)e
 By CTNB 97 (10.9) 3 (3.1) 0.001d
Tumor histology
 Adenocarcinoma 794 (88.8) 61 (7.7)
 Squamous-cell 
carcinoma
81 (9.1) 3 (3.7)
 Others 19 (2.1) 3 (15.8) 0.165
PET-CT
 Performed 61 (6.8) 4 (6.6)
 Not performed 833 (93.2) 63 (7.6) 0.971
Cons/Tumor ratiof
 ≤75% 264 (29.5) 0 (0.0) <0.001d
 >75% 630 (70.5) 67 (10.6)
aDivided into two groups according to the median age of 66 years.
bScored as the number of cigarettes smoked per day multiplied by the number of 
years since smoking started.
cPreoperative serum CEA level, normal upper limit at 5 ng/ml.
dIndicates significance.
eNo diagnosis vs. by bronchoscopy: p < 0.001, by bronchoscopy vs by CTNB: p = 
0.008.
f The maximum diameter of consolidation divided by the maximum tumor diameter 
on high-resolution computed tomography.
NSCLC, non–small-cell lung cancer; CTNB, computed tomography-guided trans-
thoracic needle aspiration biopsy; PET-CT, positron emission tomography combined 
with computed tomography; CEA, carcinoembryonic antigen.
TABLE 2.  Risk Factors for Mediastinal Nodal Metastasis in 
the 894 Patients with Clinical Stage IA NSCLC: Multivariate 
Logistic Regression Analysis and the Adjusted Odds Ratio
Variable Odds Ratio 95% CI p
Age (yr) 0.954 0.929–0.981 0.001
CEA (ng/ml) 1.054 1.010–1.100 0.017
Tumor size (mm) 1.084 1.028–1.143 0.003
Cons/tumor ratio (%) 1.126 1.053–1.204 <0.001
NSCLC, non–small-cell lung cancer; CEA, preoperative serum carcinoembryonic 
antigen level; Cons/Tumor ratio, consolidation/tumor ratio, the maximum diameter of 
consolidation divided by the maximum tumor diameter on high-resolution computed 
tomography; CI, confidence interval.
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0.598 (95% CI 0.519–0.677), 0.641 (95% CI 0.583–0.699), 
and 0.714 (95% CI 0.668–0.760), respectively. The optimal 
cutoff points were determined as: an age of 67 years, 3.5 ng/
ml for the preoperative serum CEA level, 2.0 cm for the tumor 
size on preoperative radiologic findings, and 89% for the 
Cons/Tumor ratio on HRCT. When the patients were divided 
into two groups according to the calculated cutoff points, the 
patients who were 67 years of age or younger (p = 0.016), had 
a preoperative serum CEA level of 3.5 ng/ml or more (p < 
0.001), whose tumor size on preoperative radiologic findings 
was 2.0 cm or more (p < 0.001), and had a Cons/Tumor ratio 
of 89% or more on  HRCT (p < 0.001) showed a significantly 
higher prevalence of mediastinal nodal metastasis by the uni-
variate analyses (Table 3).
Among 65 of 894 patients with all four predictors 
identified on the multivariate and ROC analyses, 22 patients 
(33.8%) developed mediastinal nodal metastasis, and among 
the remaining 829 patients, 45 patients (5.4%) developed 
mediastinal nodal metastasis. In the patients with the three or 
two predictors (n = 234 and 335, respectively), the prevalence 
of mediastinal nodal metastasis was 12.0% and 4.2%, respec-
tively. Conversely, among 50 patients without any significant 
predictors, no patients developed mediastinal nodal metasta-
sis. In addition, no patients who were 82 years of age or older 
(n = 7), those who had a CEA level less than 0.9 ng/ml (n = 
45), had a tumor size less than 1.3 cm (n = 30), or whose Cons/
Tumor ratio was 80% or less (n = 297) developed mediastinal 
nodal metastasis.
DISCUSSION
In the present study, we identified age, preoperative serum 
CEA level, tumor size on preoperative radiologic findings, 
and the Cons/Tumor ratio on HRCT as statistically significant 
FIGURE 1. Receiver operating charac-
teristic curves illustrating the capacity 
of (A) age, (B) preoperative serum CEA 
level, (C) tumor size on preoperative 
radiologic findings, and (D) (Cons/
Tumor ratio) on high-resolution CT to 
predict mediastinal lymph node metas-
tasis. Among patients with clinical stage 
IA non–small-cell lung cancer, the area 
under the curve for age, preoperative 
serum CEA level, tumor size on preoper-
ative radiologic findings, and the Cons/
Tumor ratio on high-resolution CT were 
(A) 0.597 (95%CI 0.526–0.667), (B) 
0.598 (95% CI 0.519–0.677), (C) 0.641 
(95% CI 0.583–0.699), and (D) 0.714 
(95% CI 0.668–0.760), respectively. 
CEA, carcinoembryonic antigen; Cons/
Tumor ratio, consolidation/tumor ratio; 
CT, computed tomography; AUC, area 
under the curve; CI, confidence interval.
TABLE 3.  Performance of the Cutoff Points of Risk Factors 
for Mediastinal Nodal Metastasis Determined by ROC Analysis 
and Youden’s Index in the 894 Patients with Clinical Stage IA 
NSCLC
Variable
No. of Patients 
(%)
Mediastinal Lymph Node 
Metastasis (%) p
Age
≤67 yrs 495 (55.4) 47 (9.5)
>67 yrs 399 (44.6) 20 (5.0) 0.016a
CEA
<3.5 ng/ml 641 (71.7) 35 (5.5)
≥3.5 ng/ml 253 (28.3) 32 (12.6) <0.001a
Tumor size (radiologic)
<2.0 cm 338 (37.8) 9 (2.7)
≥2.0 cm 556 (62.2) 58 (10.4) <0.001a
Cons/Tumor ratio
<89% 356 (39.8) 1 (0.3)
≥89% 538 (60.2) 66 (12.3) <0.001a
NSCLC, non–small-cell lung cancer; CEA, preoperative serum carcinoembryonic 
antigen level, normal upper limit at 5 ng/ml; Cons/Tumor ratio, consolidation/tumor ratio, 
the maximum diameter of consolidation divided by the maximum tumor diameter on 
high-resolution computed tomography.
aIndicates significance.
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predictors for mediastinal lymph node metastasis in clinical 
stage IA NSCLC patients. The ROC analyses determined the 
optimal cutoff points as 67 years for age, 3.5 ng/ml for the pre-
operative serum CEA level, 2.0 cm for the tumor size on preop-
erative radiologic findings, and 89% for the Cons/Tumor ratio 
on HRCT. Among the patients with all of  these four predictors, 
the prevalence of mediastinal nodal metastasis was 33.8%.
Even small and early-stage NSCLC patients show medi-
astinal node involvement.2–5 Because pathologically diagnosed 
nodal metastasis postresection in early-stage NSCLC is a strong 
predictor for poor survival,6 and if mediastinal nodal metasta-
sis is identified preoperatively, those patients might benefit from 
neoadjuvant therapy followed by surgery.8,9 Therefore, accurate 
preoperative mediastinal staging is important even in early-stage 
NSCLC patients. However, lymph node staging by radiologic 
modalities, such as CT and PET-CT, has some limitations.10,11
Several invasive tests are available to stage the medias-
tinum to confirm more accurately the presumptive mediastinal 
stage with radiologic modalities.13 Mediastinoscopy is a safe 
technique and the current “gold standard”  for mediastinal 
staging in NSCLC patients.19 It seems to be very good in rul-
ing out mediastinal node involvement in patients with normal-
sized nodes because of the low false negative rate13; however, 
patients without N2 disease (i.e., the true negatives and the 
pathological N0 patients) do not benefit, and thus might be 
harmed as there is no benefit to counterbalance the risks and 
the cost.20 EBUS-TBNA is a minimally invasive method of 
mediastinal biopsy, and results similar to mediastinoscopy for 
mediastinal staging in NSCLC patients have been reported.12,21 
Nevertheless, for physicians, the low prevalence of mediastinal 
nodal metastasis in early-stage NSCLC patients14 could still 
be a reason for hesitation in performing such modalities in 
those patients. Thus, in the present study, we sought to deter-
mine a high-risk population for mediastinal nodal metastasis 
in clinical stage IA NSCLC patients, which would be suitable 
for mediastinal node assessment by such invasive modalities.
Because more than 60% of patients still undergo 
unnecessary invasive tests even among the patients with all 
four predictors identified in the current study, it is difficult 
to establish an appropriate subgroup with a sufficiently high 
prevalence of mediastinal nodal metastasis in clinical stage 
IA NSCLC patients for mediastinal node assessment by inva-
sive modalities. However, we believe that the patients with the 
four predictors should at least be a target for mediastinal stag-
ing by invasive modalities; otherwise we would not be able to 
perform such invasive tests in any clinical stage IA NSCLC 
patients because of the low prevalence of mediastinal nodal 
metastasis, in such patients, the opportunity to detect occult 
nodal metastasis before surgery would be missed despite 
accurate preoperative mediastinal staging being important in 
selecting the optimal treatment. Moreover, we think that medi-
astinal node assessment by such invasive modalities might be 
considered in the patients with three, two, or not all the four 
predictors with the prevalence of mediastinal nodal metastasis 
of 12.0%, 4.2%, and 5.4%, respectively, although the preva-
lence of mediastinal nodal metastasis was lower compared 
with that in patients with the all four predictors. In contrast, 
none of the patients with no significant predictor, age 82 years 
or more, CEA level less than 0.9 ng/ml, tumor size less than 
1.3 cm or Cons/Tumor ratio 80% or less developed mediasti-
nal nodal metastasis. We might be able to skip invasive tests 
for preoperative mediastinal assessment in those subgroups of 
clinical stage IA NSCLC patients.
Asamura et al.3 reported that the prevalence of medi-
astinal nodal metastases increases with tumor size. In their 
report, among patients with resected peripheral NSCLC, 
the prevalence of nodal metastases increased from 19.5% in 
tumors 2 cm or smaller to 32.5% in tumors 2 cm to 3 cm in 
size. Previously, a larger radiologic tumor size and radiologic 
tumor size of more than 3 cm were identified as risk factors 
for mediastinal nodal metastasis.10,14,22 The current study dem-
onstrated that radiologic tumor size is a significant predictor 
even in patients with a small tumor of 3 cm or less in size. The 
ROC analysis determined the optimal cutoff point at 2 cm, and 
it was same as the point dividing T1a and T1b on the current 
TNM staging system. This result might encourage the sur-
geons conducting prospective studies of intentional sublobar 
resection for NSCLC patients with a peripheral tumor of 2 cm 
or less in size.23,24
Several reports have indicated that elevated preoperative 
serum CEA levels are associated with pathologic upstaging and 
an unfavorable prognosis after curative surgical resection in 
NSCLC patients,25,26 and preoperative serum CEA level of 5.0 
ng/ml was reported as a risk factor for mediastinal nodal metas-
tasis in the patients with resected adenocarcinoma or squamous-
cell carcinoma.10 Even in the present study, preoperative serum 
CEA level was identified as a predictor for mediastinal nodal 
metastasis, and the ROC analysis determined the cutoff point 
at 3.5 ng/ml, despite having set the cutoff for the normal upper 
limit at 5 ng/ml. This result suggested that clinical IA NSCLC 
patients with a preoperative serum CEA level of 3.5 ng/ml and 
more have a higher risk of mediastinal nodal metastasis even 
though the serum CEA level is within the normal range.
The Cons/Tumor ratio on HRCT was proposed by Suzuki 
et al.,16 and they demonstrated an accurate correlation between a 
low Cons/Tumor ratio and pathologically diagnosed noninvasive 
lung adenocarcinoma. Because a high Cons/Tumor ratio, imply-
ing a low ground-glass opacity component on HRCT, reflects 
the low proportion of noninvasive lung adenocarcinoma,27,28 and 
the majority of patients (88.8%) in the present study had adeno-
carcinoma, the association between a high Cons/Tumor ratio on 
HRCT and higher prevalence of mediastinal nodal metastasis 
seems reasonable. On the ROC analyses, the Cons/Tumor ratio 
on HRCT showed the highest AUC value of 0.714, and was 
indicated as the most accurate predictor among the identified 
four predictors. In fact, 297 of total 894 patients (33.2%) with a 
tumor having a Cons/Tumor ratio of 80% and less on HRCT did 
not develop mediastinal nodal metastasis.
Interestingly, younger age was also identified as a sig-
nificant predictor for mediastinal nodal metastasis. Given that 
the younger patients had more advanced disease compared 
with older patients in treated lung cancer patients,29,30 this 
might be one possible explanation.
Because PET-CT evaluation has been available only since 
2010, the number of patients who underwent PET-CT in this 
study was too small (n = 61, 6.8%). No definitive conclusion 
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was established in the usefulness of PET-CT for mediastinal 
assessment in clinical stage IA NSCLC patients from this study. 
In four patients with false negative mediastinal lymph nodes 
on PET-CT, one patient had micro metastasis of 1 mm in sta-
tion seven on pathological examination (data not shown), and 
this might be one possibility for false negative. However, two 
of those four patients had three predictors identified in the cur-
rent study, and this suggests that the predictors identified in the 
current study could be helpful in identifying a higher risk sub-
group for mediastinal nodal metastasis even in clinical stage IA 
NSCLC patients with negative nodes on PET-CT.
We acknowledge that the present study has some limita-
tions. Because the study was retrospective, prospective or ran-
domized trials are required for a definitive conclusion. Moreover, 
PET-CT was performed in a limited number of patients, and this 
might have affected the characteristics of clinical N0 patients in 
this study. However, we have examined a relatively large number 
of patients overall, and we believe that our results will be helpful 
in identifying the clinical stage IA NSCLC patients suitable for 
mediastinal node assessment by invasive modalities.
In conclusion, we retrospectively reviewed 894 
patients with clinical stage IA NSCLC who have undergone 
surgical pulmonary resection with systematic mediastinal 
lymphadenectomy at the Niigata Cancer Center Hospital in an 
attempt to investigate independent predictors for mediastinal 
lymph node metastasis. Age, preoperative serum CEA level, 
tumor size on preoperative radiologic findings, and the 
Cons/Tumor ratio on HRCT were identified as statistically 
significant predictive risk factors. Among the patients with 
all four of these predictors (≤67 years of age, a preoperative 
serum CEA level of ≥3.5 ng/ml, a tumor size ≥2.0 cm on 
preoperative radiologic findings, and Cons/Tumor ratio ≥89% 
on HRCT), the prevalence of mediastinal nodal metastasis was 
33.8%, compared with 7.5% in overall patients. Clinical stage 
IA NSCLC patients in whom all four predictors have been 
identified should be a target for mediastinal node assessment by 
invasive modalities, such as mediastinoscopy or EBUS-TBNA.
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